PTK2 and head and neck squamous cell carcinoma: Ex vivo cultures of HNSCC tumor samples taken directly from patients were used to assess the efficacy of the FAK inhibitor PF-562,271 or the combination of BMS754807 and dasatinib (Fig. 6A).